Catalyst

Slingshot members are tracking this event:

Clovis (CLVS) Presents Data on Two Phase 2 Studies of Rucaparib in Treatment-Resistant Ovarian Cancer at the European Society for Medical Oncology 2016 Congress

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CLVS

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 07, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Ariel2, Study 10, European Society For Medical Oncology, Rucaparib, Treatment-resistant Ovarian Cancer